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Typical cognitive aging is often defined as aging free of dementia, and yet it does not seem to exclude
dementia-related pathology. The most common type of dementia is Alzheimer’s disease (AD) – it is
a progressive neurodegenerative disease that affects multiple cognitive domains, including memory,
attention, reasoning, judgment, language, as well as behavior. AD accounts for 60–80% of dementia
cases, currently affecting 35 million people worldwide and progressing toward an estimated 115
million by the year 2050 (Riedel, 2014). Since there is no cure for AD, the research focus has
shifted from the symptomatic stage to the earlier stages of the disease, with the goal to develop
treatments that would effectively delay the onset of symptoms and progression of this devastating
disease (Selkoe, 2012; Bateman, 2015). The need to diagnose and begin treatment even before overt
symptoms appear has generated in neurological researchers a strong interest in cognitively healthy
people who are at risk for AD. Recent modifications of the research and diagnostic criteria for AD
reflect this trend by including cognitively normal (CN) at-risk-for-AD persons as a preclinical stage
in the AD continuum (Dubois et al., 2007, 2010; Sperling et al., 2011).
Crucial in themodified criteria for AD is the concept of biomarkers of Alzheimer’s pathology, i.e.,
physiological and anatomical parameters that can be objectively measured to establish the presence
of changes due to the disease (Jack and Holtzman, 2013). Since amyloid-β neuritic plaques and
neurofibrillary tangles have been established as the pathological hallmarks of AD, biomarkers of
amyloidosis and neurodegeneration are used as in vivo indicators of the presence of Alzheimer’s
pathology (Dubois et al., 2007, 2010; Sperling et al., 2011; Jack and Holtzman, 2013). The most
validated AD biomarkers are cerebrospinal fluid (CSF) amyloid-β1–42, total tau and phosphorylated
tau as pathophysiological biomarkers of Alzheimer’s pathology, and brain regional structural and
metabolic changes, as topographical biomarkers (Dubois et al., 2007; Jack and Holtzman, 2013).
However, it has been recently recognized that the topographicalmarkers lack pathological specificity
necessary for diagnosis, and that they are more useful for measuring the disease progression
(Dubois et al., 2014). According to this view, in vivo evidence of Alzheimer’s pathology, and thus
preclinical AD stage, would constitute increased cerebral amyloid burden/decreased CSF amyloid
level together with increased levels of total tau and phospho-tau. The general idea is that if a person
with Alzheimer’s pathology lives long enough, they will eventually progress to AD dementia. Thus,
biomarkers-based diagnosis provides an opportunity to introduce early treatments that will attempt
to delay appearance of dementia symptoms and disease development.
While the value of early diagnosis is beyond any dispute, the question of how to disentangle typical
aging and preclinical AD remains open. This issue is further complicated by the heterogeneous
nature of the preclinical AD. According to onemodel, preclinical AD comprises three stages: at stage
1, only brain amyloidosis is evident; at stage 2, both cerebral amyloidosis and neurodegeneration
are present; and at stage 3, these features are further combined with subtle cognitive changes
(Sperling et al., 2011). Two additional stages have been added to thismodel: stage 0, which represents
cognitively intact people without brain amyloidosis, neurodegeneration, or subtle cognitive changes,
and suspected non-amyloid pathology (SNAP), which is characterized by normal amyloid markers
and abnormal neurodegeneration markers and which is not necessarily related to AD (Jack et al.,
2012). While it is clear that preclinical AD is characterized by the absence of cognitive impairment
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on objective measures of cognition, subtle cognitive changes that
have been associated with this stage of disease remain poorly
understood (Dubois et al., 2014).
Anothermodel of preclinical AD has recently been proposed in
the context of a cross-sectional study that assessed a population-
based sample of 985 CN people aged 50–89. The model combines
only amyloidosis [positive (A+) or negative (A )] and neurode-
generation [positive (N+) or negative (N )] status, leaving out
subtle cognitive changes. The study revealed that the estimated
population frequency of the A N  sequence was 100% at age 50,
but only 17% at age 89, with the A+N+ sequence reaching 42% by
age of 89, whereas the frequency of the sequence A N+ was 24%
by that age (Jack et al., 2014). Examples of pathological sequences
leading to AD dementia are as follows: A N  to A+N  to
A+N+, and A N  to A N+ to A+N+, whereas the two com-
ponent sequence A N  to A N+ is linked to heterogeneous
underlying pathology (Jack et al., 2014). However, the neurode-
generative status in this study was determined based on topo-
graphical biomarkers of AD, more specifically by an AD signature
18F-fluorodeoxyglucose (18F-FDG) PET and hippocampal volume
on MRI. These topographical markers are not unique markers
of Alzheimer’s pathology; for example, hippocampal volume is
reduced in other conditions, such as frontotemporal demen-
tia, hippocampal sclerosis, Lewy-related pathology, argyrophilic
grain disease, diabetes, and bipolar disorder, among others (Jack
et al., 2012; Dubois et al., 2014). Thus, although these findings
still suggest that pathological aging is a predominant way of cog-
nitive aging, they also indicate a need for consensus on which
biomarkers are suggestive of Alzheimer’s pathology only and thus
better suited for untangling preclinical AD and the healthy brain
aging.
As models of preclinical AD continue to develop, a challenge
to the field is to reconcile the evidence of AD-related pathology
found in a large number of CN elderly people (Jack et al., 2012,
2014)with the notion of “healthy” or “successful” aging (Rowe and
Kahn, 1987). This evidence seems to question the research prac-
tice of not considering possible presence of Alzheimer’s pathology
in CN elderly participants when including healthy elderly per-
sons in cognitive studies. However, without the actual evidence
to exclude Alzheimer’s pathology, one can assume that some
percentage of CN elderly subjects in such studies may represent
preclinical AD. This problem has been occasionally recognized
(Gold et al., 2013; Brier et al., 2014). It clearly requires a systematic
change in approach, because subtle cognitive changes, reliance on
cognitive strategies, and networks’ reorganization that one would
interpret as the effects of healthy aging might actually reflect
the disease progression. While the number of studies investigat-
ing that the impact of atrophy, hypometabolism, white matter
changes, and ApoE4 on cognitive processes across the AD stages
is consistently growing, possible effects of β-amyloid, t-tau, and
p-tau on cognitive processes in preclinical AD remain largely
unexplored (Riedel, 2014).
Finally, in addition to apparently small percentage of CN per-
sons who despite an advanced age resist Alzheimer’s pathology
(Jack et al., 2012, 2014), there exist so-called SuperAgers. These
are elderly people (80+) who appear to have healthy brains and
well-preserved memory abilities. A recent study involving 12
SuperAgers found that their memory abilities were comparable to
those of a group of healthy 50- and 65-year-old persons. When
compared to a group of healthy age-matched peers on measures
of cortical thickness, the SuperAgers had significantly thicker
cerebral cortex. Furthermore, the left anterior cingulatewas signif-
icantly thicker in SuperAgers compared to both groups (Harrison
et al., 2012). Thus, we find not only neuropathology but also
healthy brains and preserved memory at well-advanced age.
In conclusion, it is now possible to establish the pres-
ence/absence of Alzheimer’s pathology in vivo by measuring
parameters that indicate biological changes caused by AD, thereby
determining if a person is at risk for developingAD. Incorporating
such evidence into cognitive aging research allows a differenti-
ation of possible influences of Alzheimer’s pathology from the
effects of healthy aging on cognitive processes. Only by systemat-
ically incorporating such evidence in research on cognitive aging,
we will be able to make a progress in disentangling preclinical AD
from healthy cognitive aging.
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